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Abstract
Background: a2-adrenergic receptors (ARs) mediate many cellular actions of epinephrine and norepinephrine and
inhibit their secretion from adrenal chromaffin cells. Like many other G-protein coupled receptors (GPCRs), they
undergo agonist-dependent phopshorylation and desensitization by GPCR Kinases (GRKs), a phenomenon recently
shown to play a major role in the sympathetic overdrive that accompanies and aggravates chronic heart failure.
A deletion polymorphism in the human a2B-AR gene (Glu301-303) causes impaired agonist-promoted receptor
phosphorylation and desensitization in heterologous cell lines. Given the importance of a2-ARs in regulation of
catecholamine secretion from chromaffin cells, we sought to investigate, in the present study, the desensitization
properties and the sympatho-inhibitory activity of this variant in a chromaffin cell line. For this purpose, we
expressed this variant and its wild type counterpart in the well-established chromaffin cell line PC12, and
performed receptor phosphorylation and desensitization studies, as well as in vitro catecholamine secretion assays.
Results: Both the agonist-induced phosphorylation and agonist-dependent desensitization of the human Glu301-
303 deletion polymorphic a2B-AR are significantly impaired in PC12 cells, resulting in enhanced signaling to
inhibition of cholinergic-induced catecholamine secretion in vitro.
Conclusion: This a2B-AR gene polymorphism (Glu301-303 deletion) might confer better protection against
conditions characterized and aggravated by sympathetic/catecholaminergic overstimulation in vivo.
Background
Three distinct a2-adrenergic receptor (a2-AR) subtypes
(a2A, a2B, a2C) that mediate many of the physiological
actions of the catecholamines (CAs) epinephrine (Epi)
and norepinephrine (NE) have been described [1]. They
belong to the family of G-protein coupled or seven
transmembrane-spanning receptors (GPCRs or 7TMRs)
and they are linked to the inhibitory Gi/o proteins [1].
The a2B-AR is critically involved in cardiovascular regu-
lation, as its gene disruption in mice affects blood pres-
sure responses to a2-adrenoceptor agonists (e.g.
clonidine) [2]. Its role in the Central Nervous System
(CNS) remains largely elusive. It may be important in
developmental processes, since homozygous a2B-KO
mice do not breed well [2].
Like many other GPCRs, the a2B-AR undergoes ago-
nist promoted desensitization [3] initiated by the phos-
phorylation of the receptor in its third intracellular loop
by a well-characterized family of serine/threonine
kinases termed G protein-coupled receptor kinases
(GRKs), the most prominent member of which is the
ubiquitously expressed GRK2 [4]. The phosphorylated
receptor then interacts with a certain family of proteins
termed arrestins, which physically uncouple the receptor
from G proteins, thus terminating receptor signaling [4].
a2-ARs play a very important role in autocrine feed-
back regulation of catecholamine secretion from the
chromaffin cells of the adrenal medulla [5]. By coupling
to the Gi/o proteins, they inhibit further CA release
upon their stimulation by the secreted CA, thereby par-
ticipating in an autocrine negative feedback loop con-
trolling adrenal CA secretion [5,6]. A number of recent
studies by our group and others have documented the
(patho)physiological importance of this a2-AR-mediated
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control of adrenal CA secretion, as deregulation of this
signaling system in the adrenal chromaffin cells has
been shown to underlie excessive sympathetic outflow
and circulating CA levels that accompany and aggravate
chronic heart failure [7-9]. More specifically, up-
regulated GRK2 has been found to desensitize and
down-regulate chromaffin cell a2-ARs extensively in HF
mouse and rat adrenal glands, thus rendering these
receptors nonfunctional in HF. This allows for unop-
posed, continuous CA secretion, which contributes to
the enhanced CA levels in heart failure [7].
A common genetic variant of the a2B-AR subtype
consisting of a deletion of three glutamic acid residues
(residues 301-303) displays impaired agonist-promoted
receptor phosphorylation and desensitization in various
transfected cell lines [10,11], and, very recently, it was
shown to be resistant to desensitization (in terms of
inducing vasoconstriction) in vivo, as well [12]. Given
the important role of a2-ARs in chromaffin cell physiol-
ogy with respect to CA secretion regulation, in the pre-
sent study we sought to investigate the impact of this
a2B-AR polymorphism on desensitization and sym-
patho-inhibitory function of this receptor in these cells.
To this end, we utilized the PC12 cell line, a rat pheo-
chromocytoma-derived chromaffin cell line [13], which
we transfected with the wild-type a2B-AR (WT a2B-AR)
or the polymorphic a2B-AR (Del a2B-AR) cDNA con-
structs in order to express and compare head-to-head
these two receptor variants in chromaffin cells. We
found that desensitization of the Del a2B-AR is impaired
also in PC12 cells, which results in enhanced inhibition
of CA secretion.
Results
Impaired agonist-promoted phosphorylation of the Del
a2B-AR in PC12 cells
After verifying that PC12 cells express substantial endo-
genous levels of both GRK2 and GRK3, more than suffi-
cient to phosphorylate a2-ARs (data not shown), we
performed whole cell phosphorylation studies of the two
receptors in PC12 cells in response to 10 min treat-
ments with 10 μM UK14304, an a2-AR-specific full ago-
nist, or vehicle. Since GRKs are serine/threonine
kinases, we used a specific polyclonal anti-phosphoserine
antibody (anti-P-Ser) to examine the receptors’ agonist-
induced phosphorylation. As shown in Figure 1A, the
Del a2B-AR displays indeed a dramatically decreased
agonist-promoted phosphorylation compared to the
WT a2B-AR. More specifically, WT a2B-AR displays
~3.5-fold increase in phosphorylation in response to
agonist, whereas agonist-induced phosphorylation of the
Del a2B-AR is virtually abolished (Figure 1B). Of note,
GRK2 levels were equal between the two a2B-AR-
expressing PC12 lines, indicating that Del a2B-AR
transfection and overexpression did not have any effects
on endogenous GRK2 levels in PC12 cells (data not
shown).
Impaired agonist-promoted desensitization of the Del
a2B-AR in PC12 cells
We next examined the impact of this impaired phosphory-
lation on the functional desensitization, i.e. on the agonist-
induced G-protein coupling, of the Del a2B-AR with the
[35S] GTPgS binding assay. This assay is widely used to
measure the G-protein coupling efficiency of GPCRs [14].
Again, we treated the PC12 cells with 10 μM UK 14304
for 30 minutes or with vehicle, and then membranes were
prepared from these cells and the [35S] GTPgS binding
assay was performed on these membranes using again
10 μM UK 14304 as agonist. As shown in Table 1 and in
Figure 2A, the two non-agonist-pretreated receptors (Con-
trols) exhibit about the same agonist-stimulated [35S]
GTPgS binding (240 ± 13% of basal for the WT a2B-AR
and 221 ± 15% of basal for the Del a2B-AR). However, the
agonist-pretreated WT a2B-AR displays a significantly
decreased agonist-stimulated [35S] GTPgS binding (114 ±
18% of basal), compared to the Control WT a2B-AR,
which reflects a significant functional desensitization of
this receptor (~53%). In contrast, the agonist-pretreated
Del a2B-AR shows almost the same agonist-stimulated
[35S] GTPgS binding (208 ± 20% of basal) as the Control
Del a2B-AR, indicating that the Del a2B-AR fails to
undergo desensitization in PC12 cells.
In addition, GTPgS binding dose-response curves
of Epi-pretreated cells revealed a significant increase
(1.8-fold, p = 0.012) in the EC50 of Epi to stimulate
GTPgS binding through the WT a2B-AR, whereas Epi
pretreatment did not induce significant changes on the
EC50 for the Del a2B-AR (Figure 2B). This result pro-
vides additional strong evidence that the Del a2B-AR, in
contrast to its wild type counterpart which undergoes
agonist-induced desensitization normally as expected,
fails to desensitize in PC12 cells. This impaired desensi-
tization of the Del a2B-AR comes as a consequence of
its impaired agonist-induced phosphorylation in PC12
cells.
Enhanced inhibition of catecholamine secretion by the
Del a2B-AR in PC12 cells
Finally, we examined the functional impact of this
impaired phosphorylation/desensitization of the Del
a2B-AR in PC12 cells, and, more specifically, the impact
on the ability of the receptor to inhibit CA secretion.
Physiologically in chromaffin cells, CA secretion is toni-
cally stimulated by acetylcholine acting on nicotinic cho-
linergic receptors endogenously expressed in chromaffin
cell membranes [5]. Thus, we performed in vitro CA
secretion assays in the PC12 cells using nicotine (which
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also stimulates nicotinic cholinergic receptors) as the
stimulus for the CA secretion and UK14304 as the ago-
nist for the a2B-ARs. As shown in Figure 3 nicotine
induced comparable amounts of CA secretion from the
two transfected and UK14304-pretreated PC12 cell lines.
Of note, when no challenge with UK14304 preceded
nicotine exposure, CA secretion between the two cell
lines was similar (data not shown). However, when the
cells were pretreated with UK14304 to induce desensiti-
zation of the a2B-ARs, secretion of both Epi and NE
from the UK14304-pretreated PC12a2BDel cells was sig-
nificantly reduced compared to agonist-pretreated
Figure 1 The Del a2B-AR displays impaired agonist-promoted phosphorylation in PC12 cells. A. Transfected PC12 cells were exposed to
10 μΜ UK 14304 for 10 min and then immunoprecipitation (IP) of the a2B-ARs was performed, followed by immunoblotting (IB) to measure
their phosphoserine (P-Ser) content. Equal amounts of receptor were loaded on each lane, as determined from ligand binding data and protein
determination by the Bradford method. Shown is a representative blot from five independent experiments. B. Densitometric analysis of the
immunoblots of Panel A, showing agonist-induced receptor phosphorylation as fold increase of the basal phosphorylation of WT a2B-AR. *, p <
0.05, vs. all other conditions, n = 5.
Nguyen et al. Cell Communication and Signaling 2011, 9:5
http://www.biosignaling.com/content/9/1/5
Page 3 of 8
PC12a2BWT cells, indicating that the impaired desensiti-
zation of the Del a2B-AR allows it to be a stronger inhi-
bitor of CA secretion from PC12 cells, compared to its
wild-type counterpart (Figure 3).
Notably, and because UK14304 is largely reported in the
literature to be a partial agonist at the a2B-AR subtype, we
repeated these experiments with another, full a2B-AR ago-
nist, oxymetazoline, and the results were identical (data
not shown). Thus, diminished desensitization of the Del
a2B-AR mutant seems to translate into enhanced inhibi-
tory function of the receptor on CA secretion from PC12
cells, regardless of the structure or the individual pharma-
cological properties of the activating agonist.
Discussion
A polymorphic variant of the human a2B-adrenoceptor,
which consists of a deletion of three glutamic acids
(residues 301-303) in the third intracellular loop (Del
a2B-AR) has been identified [15] and characterized in
transfected CHO-K1 cells [10]. Given the important role
of a2-ARs in chromaffin cell physiology with respect to
CA secretion regulation [2,7] in the present study we
sought to analyze the properties of this polymorphic
receptor in PC12 cells, a very well established and
widely used chromaffin cell line [13]. In particular, we
wanted to see whether the phenotype of the impaired
phosphorylation and desensitization of the Del a2B-AR
also applies in chromaffin cells, and, if so, what conse-
quences this might have on the CA secretion inhibitory
(sympatho-inhibitory) function of the receptor in these
cells. We found that the agonist-promoted phosphoryla-
tion and subsequent desensitization of the Del a2B-AR
is indeed dramatically impaired in PC12 cells, as well. In
particular, it appears that the agonist-induced (i.e. GRK-
mediated) phosphorylation and desensitization of the
Del a2B-AR are deficient, since both of these receptor
Table 1 Agonist-stimulated [35S] GTPgS binding




Cpm/min/15 μg % %
WT a2B-AR 2983,15 ± 09,74 240,01 ± 13,02 113,74 ± 18,40
a 53
Del a2B-AR 5717,39 ± 13,02
b 221,15 ± 14,94 208,47 ± 19,93b 6
Agonist-stimulated [35S]GTPgS binding was determined in response to 10 μM
UK14304 (agonist) in agonist-pretreated (UK14304) and in non-pretreated
(Control) membranes. Des. = Desensitization.
a p < 0.05 compared with control, b p < 0.05 compared with WT, n = 6
independent experiments.
Figure 2 [35S] GTPgS binding for the two a2B-ARs in PC12 cells. A. PC12 cells were exposed to vehicle (Control) or 10 μM UK14304 (Agonist-
pretreated) and agonist-stimulated [35S] GTPgS binding was determined. Results are expressed as % of basal binding, indicating a ~ 53%
desensitization of the WT a2B-AR (see also Table 1). *, p < 0.05, vs. Control WT a2B-AR, n = 6 independent experiments. B. Membranes from control
(Control) and 10 μM epinephrine-pretreated (Epi) cells were incubated with increasing concentrations (c) of epinephrine. Only the Epi-pretreated
WT a2B-AR displays decreased [
35S] GTPgS binding (i.e. desensitization) in response to Epi, whereas the Del a2B-AR fails to do so. *, p < 0.05, vs. Epi,
n = 6 independent experiments.
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properties were studied in response to agonist stimula-
tion (UK14304). This is entirely consistent with what
has been observed for this receptor variant in another
heterologous (but physiologically irrelevant) cell line
(COS-7) and in neuronal cells [10,11].
Importantly, in the present study, we report that this
impaired phosphorylation and desensitization of the Del
a2B-AR in PC12 cells leads to enhanced inhibition of Epi
and NE secretion by the receptor in this chromaffin cell
line. This novel phenotypic/functional finding for this
polymorphism is therefore now added to the ever-expand-
ing, over the past several years, list of its (genetic)
associations with low basal metabolic rate in some obese
populations [15], with acute coronary events [16] and
increased risk of sudden cardiac death [17], with impaired
endothelial function as assessed by flow-mediated dilata-
tion of the brachial artery [18], with elevated blood pres-
sure in conjunction with stressful work environment [19],
with risk reduction for incident diabetes after dietary
changes [20], with impaired first-phase insulin secretion
that may predict impaired glucose tolerance [21], with
reduced autonomic responsiveness by altering cardiac
sympathetic and vagal function during sustained handgrip
exercise in normotensive obese women [22], and with
Figure 3 Enhanced inhibition of nicotine-induced catecholamine secretion by the Del a2B-AR in PC12 cells. In vitro catecholamine
secretion from PC12 cells, expressing the WT a2B-AR (WT) or the Del a2B-AR (Del) and pretreated with 10 μM UK14304, in response to either 50
μM nicotine alone (Nicotine) or to 50 μM nicotine plus another challenge of 10 μM UK14304 (UK14304 + Nicotine). No differences between the
two non-pretreated cell lines were observed (data not shown). *, p < 0.05, vs. WT/Nicotine, **, p < 0.05, vs. WT/UK14304 + Nicotine, n = 3
independent experiments.
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depressed general autonomic tone and impaired vagal
activity in non-diabetic men, which is accentuated by cen-
tral obesity [23].
Given that a2-ARs of the sympathetic nerves and adre-
nal glands are crucial regulators of SNS activity/outflow
and of circulating CA levels in heart failure and in other
diseases characterized and aggravated by sympathetic
overactivity, by virtue of inhibiting CA secretion and NE
release from sympathetic nerve terminals [5], the finding
of enhanced inhibition of CA secretion from chromaffin
cells by the Del a2B-AR reported in the present study is
of obvious physiological importance. It strongly implies
that carriers of this a2B-AR polymorphism might have
lower levels of sympathetic outflow, since this poly-
morphic variant displays enhanced sympatho-inhibitory
function due to its impaired desensitization (i.e. termina-
tion of signaling). In fact, its previously reported associa-
tions with reduced autonomic responsiveness by altering
cardiac sympathetic and vagal function and with
depressed general autonomic tone and impaired vagal
activity [22,23] are entirely consistent with the above pos-
tulated effect of this polymorphic a2B-AR on sympathetic
outflow in vivo.
It is worth noting that whether the a2B-AR subtype is
endogenously expressed in adrenal chromaffin cells, and
in particular in human adrenal chromaffin cells, and
participates therein in regulation of CA secretion, is
somewhat a matter of debate [5], making the present
findings difficult to interpret physiologically. There is
however one reported function of a2B-AR when
expressed in PC12 cells, and that is stimulation of neu-
ronal differentiation of these cells upon chronic epi-
nephrine treatment [24,25]. Thus, in that context, and
based on the findings of the present study, this poly-
morphic Del a2B-AR would be expected to stimulate
neuronal differentiation of PC12 cells to an even higher
extent than its wild-type counterpart.
There appears to be a species-dependent variation in
the particular adrenal a2-AR subtypes expressed and
some contradictory data have been reported in the lit-
erature, even for the same species [5]. In fact, our pre-
vious study has indicated that only the a2A subtype is
present endogenously in rat adrenal chromaffin cells
(the species that PC12 cells also originate from), and
this appears to be the case also in human adrenal glands
[7]. Making matters even more complex, PC12 cells do
not express any adrenoceptors at appreciable levels
endogenously [24,26]. Nevertheless, based on our pre-
sent findings, it is entirely legitimate to speculate that
this polymorphic a2B-AR will exert enhanced feedback
inhibition of CA release, if present in human adrenal
chromaffin cells or wherever in the CNS and in periph-
eral sympathetic nerve terminals it is expressed in
humans in vivo. Therefore, carriers of this a2B-AR gene
polymorphism might be better protected and experience
less severe symptoms from pathological conditions and
diseases characterized and aggravated by sympathetic/
catecholaminergic overstimulation in vivo, including
(but not limited to) heart failure, hypertension, and
hyperthyroidism.
Conclusions
A deletion polymorphism in the human a2B-AR gene
confers impaired agonist-dependent receptor phosphory-
lation and desensitization also in the adrenal chromaffin
cell line PC12, resulting in enhanced inhibitory function
against cholinergic-induced catecholamine secretion in
vitro. Thus, this a2B-AR gene polymorphism might con-
fer better protection against conditions characterized
and aggravated by sympathetic/catecholaminergic over-




Guanosine diphosphate (GDP), Guanosine 5 ’-O-
(3-thiotriphosphate) (GTPgS), nicotine, epinephrine,
5-bromo-6-(2-imidazoline-2-ylamino)-quinoxaline
(UK14304), and oxymetazoline were from Sigma-
Aldrich (St. Louis, MO). The anti-phosphoserine (anti-
P-Ser) rabbit polyclonal antibody was from Chemicon
(Temecula, CA). The anti-a2B-AR and anti-GRK2/3
antibodies were from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA). [35S] Guanosine 5’-O-(3-thiotripho-
sphate), [35S] GTPgS was from Amersham Pharmacia
Biotech (Buckinghamshire, UK).
Cell lines, transfection and cell culture
The cDNA of the human a2B-AR (Missouri S&T cDNA
Resource Center, Rolla, MO, USA) was modified
(Del322-325) using polymerase chain reaction-mediated
mutagenesis (Stratagene Cloning Systems, La Jolla, CA).
PC12 cells were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA) and transfected
with the constructs of interest (i.e. wild type or Del
a2B-AR) via the Lipofectamine method (Invitrogen,
Carlsbad, CA, USA). For comparison of the properties
of the two receptors, cell lines with comparable expres-
sion levels were chosen, as determined by ligand binding
with the a2AR-specific antagonist [
3H]-rauwolscine (3.1
pmol/mg of protein for PC12a2BWT, 2.95 pmol/mg of
protein for PC12a2BDel). The culture of PC12 cells was
performed, as described previously [13].
Receptor phosphorylation studies
After a 10 min stimulation with UK14304 or vehicle
PC12 cells were washed three times with ice-cold phos-
phate-buffered saline and solubilized in 1 ml of a buffer
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containing 1% Triton X-100, 0.1% SDS, 20 mM Tris-Cl
pH 7.5, 125 mM NaCl, 1 mM MgCl2 and 1 mM CaCl2,
protease and phosphatase inhibitors. The a2B-ARs were
immunoprecipitated with a specific anti-a2B-AR anti-
body and subsequently, the proteins in the supernatant
were fractionated on a 12% SDS-polyacrylamide gel, fol-
lowed by western blotting with an anti-phosphoserine
(anti-P-Ser) specific antibody. Equal amounts of protein
were loaded in each lane.
[35S] GTPgS binding assay
Cell membranes were prepared by centrifugation and
agonist-induced stimulation of [35S] GTPgS binding was
measured as described previously [14]. Briefly, mem-
brane pellets were resuspended in hypotonic lysis buffer.
The reaction was started by adding an aliquot of mem-
brane suspension (15 μg of membrane protein per tube)
to reaction buffer (25 mM Tris-HCl, pH 7.4, 5 mM
MgCl2, 1 mM EDTA, 1 mM dithiothreitol, 100 mM
NaCl, 1 μM GDP, and 2 nM [35S] GTPgS) with or with-
out agonist (10 μM UK 14304) in a total volume of
100 μl. The incubation was terminated by dilution with
4 volumes of ice-cold 10 mM Tris-HCl buffer, pH 7.4,
and vacuum filtration through Whatman GF/B glass
fiber filters, which were then placed in scintillation vials
for counting in a liquid scintillation counter (Beckman
counter). Non-specific binding was measured in the pre-
sence of 10 μM GTPgS. For desensitization experiments,
cells were pretreated with 10 μM UK 14304 or 10 μM
epinephrine for 30 min at 37°C or with vehicle, placed
on ice, and washed three times with ice-cold phosphate-
buffered saline prior to membrane preparation.
In vitro catecholamine secretion assay
In vitro epinephrine and norepinephrine secretion in
response to various treatments was measured in the
supernatant of transfected PC12 cells by ELISA, as
described previously [8]. Cells were pretreated with
UK14304 (or oxymetazoline) for 30 min prior to the
nicotine challenge, and supernatant was collected at
20 min post-nicotine application.
Statistical analysis
Data are summarized as mean ± SEM. Comparisons
were made using t tests or ANOVA as appropriate.
A Bonferroni correction was applied to the probability
values whenever multiple comparisons arose. Values of
p < 0.05 were considered significant.
List of Abbreviations
α2-AR: α2-adrenergic receptor; GPCR: G-protein coupled receptor; GRK: G-
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